Long-term Eltrombopag Improves Outcomes in Chronic Immune Thrombocytopenia

Share this content:
Previous studies show that eltrombopag treatment for 6 months or less effectively increases platelet counts and reduces bleeding among patients with chronic ITP.
Previous studies show that eltrombopag treatment for 6 months or less effectively increases platelet counts and reduces bleeding among patients with chronic ITP.

This article originally appeared on ONA.

Long-term eltrombopag demonstrated efficacy in restoring platelet counts and decreasing risk of bleeding in patients with chronic/persistent immune thrombocytopenia (ITP) lasting more than 6 months, according to a study published in Blood.1

Previous studies showed that eltrombopag treatment for 6 months or less effectively increased platelet counts and reduced bleeding among patients with chronic ITP. The purpose of this analysis was to evaluate the safety and efficacy of eltrombopag long term.

For the phase 3 EXTEND trial (ClinicalTrials.gov Identifier: NCT00351468), an extension study of 4 clinical trials for eltrombopag, researchers enrolled 302 patients with chronic ITP with a starting dose of eltrombopag 50 mg daily and titrated doses accordingly. Eligible patients must have had ITP lasting for 6 months or longer and received prior treatment for the disease. 

The median duration of treatment was 2.37 years. Forty-five percent (135) of patients completed the study, and 25% (75) of patients continued treatment for 4 or more years.

Study patients experienced an increase in median platelet count to 50x109/L or greater by week 2. Approximately 86% of patients reached platelet counts of 50x109/L at least once in the absence of rescue treatment, and 52% of patients had a continuous response lasting 25 weeks or longer.

Lower rates of response were observed in patients with platelet levels lower than 15x109/L, patients who had received more previous therapies, and/or patients who underwent splenectomy.

After 1 year of treatment, bleeding symptoms decreased from 57% at baseline to 16%.

Reported adverse events that led to treatment discontinuation for 41 patients included hepatobiliary effects, cataracts, deep vein thrombosis, cerebral infarction, headache, and myelofibrosis.

Reference

  1. Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017 October 17. doi: 10.1182/blood-2017-04-748707 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters